First-line trials

Main Trials Page | Search Trials | Clinical Trial Site List | Drug Watch List

First-line Trials| Gleevec/Sutent-resistant | All Trials | Recruiting Trials | Preventative (Adjuvant)Treatment Trials

 
7 trials found

These trials are for patients that have never had Gleevec before (although some may allow previous adjuvant Gleevec, check the trial details). The intent of these trials is to try to improve on the initial response to therapy. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

Imatinib
 
Prospective Multicentric Randomized Study of Glivec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00367861 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Centre Leon Berard Lyon France
Institut Gustave-Roussy Villejuif Cedex France
Hopital Edouard Herriot Lyon France
Centre Oscar Lambret - Bordeaux Bordeaux France
Institut Bergonie Bordeaux France
Institut Paoli Calmette Marseilles France
Centre Alexis Vautrin Nancy France
Hospital de La Timone Marseille France


Imatinib
 
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT01031628 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Sarcoma Oncology Center Santa Monica CA USA


Masitinib, (AB1010)
 
Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00812240 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
MD Anderson - Orlando Orlando FL USA
Henry Ford Health System Detroit MI USA
Beth Israel Medical Center New York NY USA
Centre Oscar Lambret - Lille Lille France
Centre Leon Berard Lyon France
Centre Georges Francois Leclerc Dijon France
Hopital Charles Nicolle Rouen France
Centre Hospitalier Victor Jousselin Dreux France
Centre Rene Huguenin Saint-Cloud France
Centre Rene Gauducheau Nantes France
Hopital Jean Minjoz Besancon France
Institut Paoli Calmette Marseilles France
Centre Val d'Aurele Montpellier France
Hopital de la Source Orleans France
Hopital Europeen Georges Pompidou Paris France
Institut Bergonie Bordeaux France
Hopital Robert Debre Reims France
Hopital Saint-Georges Beirut Lebanon
Hopital Saint-Joseph Dora Lebanon
Middle East Institute of Health Bsalim Lebanon
Hamoud Hospital Saida Lebanon
American University Hospital Beirut Lebanon


Nilotinib or Imatinib
 
Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00785785 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Hematology Oncology Services of Arkansas Little Rock AR USA
City of Hope Duarte CA USA
City of Hope - Pasadena Pasadena CA USA
Stanford Cancer Center Palo Alto CA USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
University of Colorado Aurora CO USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
University of Kansas Cancer Center Westwood KS USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Dana Farber Cancer Institute Boston MA USA
University of Michigan Ann Arbor MI USA
University of Pennsylvania Philadelphia PA USA
National Cancer Center Hospital East Chiba Japan
Shizouka Cancer Center Shizuoka Japan
Aichi Cancer Center Hospital Aichi Japan
Hokkaido University Hospital Hokkaido Japan
National Cancer Center Singapore Singapore
The Cancer Institute/National University Hospital Singapore Singapore
GVI Oncoogy Panorama South Africa
Univerity of Pretoria Pretoria South Africa
Mary Potter Oncology Center Pretoria Gauteng South Africa
Sandton Oncology Centre Johannesburg Gauteng South Africa
University Hospital La Paz Madrid Spain
Consorci Hospitalari Parc Tauli Barcelona Spain
Chulalongkorn University Bangkok Thailand
Prince of Songkla University Songkla Thailand
Khon Kaen University Khon Kaen Thailand
Siriraj Hospital Bangkok Thailand
University of Pittsburgh Cancer Institute Pittsburgh PA USA
St. Luke's Hospital & Health Network Bethlehem PA USA
MD Anderson Cancer Center Houston TX USA
Simmons Cancer Center Univ. of Texas SW Medical Center Dallas TX USA
Parkland Health & Hospital System Dallas TX USA
Oncology Alliance Wauwatosa WI USA
Universitatsklinik f. Innere Medzin I Vienna Austria
Site name unknown, Sao Paulo Sao Paulo/SP Brazil
Site name unknown, Uberlandia Uberlandia/MG Brazil
Ottawa Regional Cancer Center University of Ottawa Ottawa Ontario Canada
Maisonneuve-Rosemont Hospital Montreal QC Canada
Oncologos del Occidente S.A. Pareira Colombia
Fundacion Santa Fe Bogota Bogota Colombia
Oncomedica S.A./Intituo Medico de Alta Tecnologia Monteria Colombia
Birmingham Heartlands Hospital Birmingham UK
Royal Marsden Hospital London UK
Beatson West of Scotland Cancer Centre Glasgow UK
Arhus University Hospital Arhus Denmark
Universitatsklinik f. Innere Medzin Onkologische Ambulanz Innsbruck Austria
Centro de Pesquisas Oncologicas Florianopolis Brazil
UNICAMP - Hospital das Clinicas Campinas Brazil
COT - Centro Oncologico do Triangulo Ltda. Santa Minica Uberlandia Brazil
Universidade Federal da Sao Paulo Sao Paulo Brazil
Hotel Dieu du Quebec Quebec Canada
Juravinski Cancer Center Hamilton Ontario Canada
London Regional Cancer Center London Ontario Canada
CHUS - Hospital Fleurimont Sherbrooke Quebec Canada
CHUM - Hopital Notre-Dame Montreal Quebec Canada
National Cancer Center Hospital Tokyo Japan
National Hospital Organization - Osaka General Hospital Osaka Japan
Kawasaki Medical School Hospital Okayama Japan
Kumamoto University Hospital Kumamoto Japan
Tohoku University Hospital Miyagi Japan
Niigata University Medical and Dental School Niigata Japan
Kanagawa Cancer Center Kanagawa Japan
Osaka University Hospital Osaka Japan
Mount Sinai Hospital Toronto ON Canada
Christie Hospital NHS Trust Manchester Lancashire UK
University College Hospital London UK
Medizinische Universitatsklinik Graz Graz Austria
Institut Gustave-Roussy Villejuif Cedex France
Centre Leon Berard Lyon France
Hospital de La Timone Marseille France
Kyushu University Hospital Fukuoka City Japan
Cambridge University Hospitals Cambridge UK
Rocky Mountain Cancer Centers Dencer CO USA
Ocala Oncology Center Ocala FL USA
Northeast Georgia Cancer Center (ACORN) Athens GA USA
Kootenai Cancer Center Coeur d'Alene ID USA
Pennsylvania Oncology Hematology Associates Philadelphia PA USA
Tyler Cancer Center Tyler TX USA
Leiedn University Leiden Netherlands
Sheba Medical Center Rahat Israel
Freeman Hospital - Northern Centre for Cancer Care Newcastle, UK


Dasatinib (BMS-354825)
 
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor + SRC inhibitor
NCT#:
 NCT00568750 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Centre Hospitaleir Universitaire Vaudois Lausanne Switzerland
Helsinki University Central Hospital Helsinki Finland
Centre Paul Strauss Strasbourg France
Hopital Edouard Herriot Lyon France
Institut Bergonie Bordeaux France
Institut Gustave-Roussy Villejuif Cedex France
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
City Hospital Triemli Zurich Switzerland
Hopital Cantonal Universitaire de Geneve Geneva Switzerland
Universitaetsspital-Basel Basel Switzerland
Kantonsspital Baden Baden Switzerland
Kantonsspital Bruderholz Bruderholz Switzerland
Kantonsspital Graubuenden Chur Switzerland
Kantonsspital Liestal Liestal Switzerland
Onkozentrum - Klinik im Park Zurich Switzerland
Saint Claraspital Basel Switzerland
UniversitaetsSpital Zuerich Zurich Switzerland
Kantonsspital - St Gallen St. Gallen Switzerland


Imatinib, Nilotinib
 
REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Peter McCallum Cancer Institute East Melbourne Victoria Australia
Royal Melbourne Hospital Parkville Vic Australia
Sydney Haematology and Oncology Clinics Hornsby NSW Australia
Prince of Wales Hospital Randwick NSW Australia
Calvary Mater Newcastle Waratah NSW Australia
The Tweed Hospital Tweed Heads NSW Australia
Canberra Hospital Garran ACT Australia
Box Hill Hospital Box Hill Victoria Australia
Border Medical Oncology Wodonga Victoria Australia
Princess Alexandra Hospital Woolloongabba Queensland Australia
Flinders Medical Center Bedford Park SA Australia
Ashford Cancer Center Ashford SA Australia
Royal Hobart Hospital Hobart Tasmania Australia
Christchurch Hospital Christchurch New Zealand
Palmerston North Hospital Palmerston North New Zealand


Nilotinib
 
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
 NCT00756509 Conditions: Gastrointestinal Stromal Tumor
Status:
 Recruiting
 
Site
City
State
Country
Site name unknown, Bad Saarow Bad Saarow Germany
Site name unknown, Milan Milan Italy


 
  7 Trials Found